Probiotic HN001 boosts happiness, reduces stress in NZ study, shows gender-specific effects

A recent randomised controlled trial (RCT) originating from New Zealand has demonstrated that the probiotic strain Lacticaseibacillus rhamnosus HN001 significantly enhances mental wellbeing in healthy adults. The study, funded by Fonterra Cooperative Group and published in Nutrients, found improvements in both happiness and perceived stress scores over a four-week intervention period. Researchers observed an increase in total happiness scores from a baseline of 107.1 to 121.8 in the probiotic group, compared to a rise from 106.6 to 116.5 in the placebo group. Perceived Stress Scores (PSS) for the HN001 group decreased from 24 to 14.9, against a reduction from 24.6 to 16.6 in the placebo cohort. This builds on previous preclinical and clinical studies supporting HN001's role in mental wellbeing, including positive effects on social functioning in prediabetes patients and reduced postpartum anxiety.

The double-blind, placebo-controlled trial involved 120 participants, aged 18 and above, experiencing mild to high stress. Participants consumed three capsules daily for 28 days, with the probiotic group receiving a dose of 6 × 10⁹ CFU/day of HN001. A notable finding was the sex-specific effect, with men experiencing a statistically significant improvement in happiness scores compared to the placebo group, with effects evident within two weeks. While female participants did not show statistically significant changes in happiness, 70% of females in the probiotic group reported moving from 'not happy' to 'happy', an incremental 13% over the placebo group. Researchers suggest that a longer intervention period might be necessary for women due to biological factors.

The study highlights HN001's potential in mental health support and differentiates its efficacy across genders. Although the placebo effect was observed, changes in the HN001 group were more pronounced. Further research is cited as necessary to fully understand the mechanisms of action, with potential links to immune system strengthening and reduction of subclinical inflammation. These findings supply new evidence for product formulation and targeted marketing strategies within the mental wellbeing supplement category.

What this means for New Zealand

New Zealand-based manufacturers and brand owners can leverage this domestic research to gain a competitive edge in mental wellbeing supplement markets. The Fonterra-funded study provides robust, locally sourced evidence for HN001's efficacy, which can be directly integrated into product claims and marketing materials, particularly for products targeting stress reduction and happiness. Formulation developers should consider gender-specific product lines, emphasising a 28-day consumption for men to achieve stated benefits and exploring longer regimen recommendations for women. This offers a clear differentiation opportunity in a crowded market, supported by a credible New Zealand study from Nutrients. Regulatory compliance for claims will need to align with Medsafe guidelines.

Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.